Amerita

Casey Cooper

Casey Cooper, director of clinical operations at Amerita, has 18 years of experience as a pharmacist. He focuses on home infusion therapy and has held roles ranging from staff pharmacist to pharmacy manager and business integration manager.

Ryan Coleman, senior director of enterprise data services at Amerita, brings 25 years of experience in sales, operations and advanced data analytics. In his current role at Amerita, Ryan leverages data analytics expertise to support the organization’s reporting and provide actionable insights. He delivers insights that drive operational and financial decisions, helping the company connect and care for patients effectively.

In an interview with Life Sciences Review, Cooper and Coleman share valuable insights into the latest trends shaping the specialty infusion therapy market and offer practical guidance for healthcare professionals, researchers and industry strategists.

Could You Elaborate On How Patient And Caregiver Education Contributes To Highquality Care In Specialty Infusion Therapy, Particularly In Terms Of Its Impact On Outcomes And The Overall Patient Experience? Cooper:

Patient and caregiver education is central to our approach and shapes the patient experience.

In specialty infusion therapy, we deliver medication intravenously, unlike the traditional pharmacy model where patients pick up pills at their local pharmacy. In many cases, especially in the acute infusion space, we administer therapy and teach patients to self-perform infusions at home.

Recovering at home, rather than in a nursing or rehab facility, significantly improves patient outcomes. Studies show that patients who recover at home have fewer complications, heal faster, and face lower rates of infection risk. Achieving these benefits starts with proper education from the moment we first engage with a patient and continues throughout their therapeutic journey. Education is a key focus because well-informed patients experience improved outcomes and recoveries. Many home infusion clinicians agree that beyond clinical duties, a key role is educating patients to manage their therapy confidently, so they can heal comfortably at home.

What Are The Most Significant Trends And Technological Advancements In Pharmaceutical Manufacturing That You Believe Will Have The Most Significant Impact On The Infusion Market?

Cooper:

A significant trend in specialty infusion therapies is the increasing reliance on infusion-based drugs. By 2025, over two-thirds of new drugs will belong to this category. This shift stems from scientific breakthroughs that originated with the Human Genome Project in the 1990s. The project allowed researchers to map the human DNA sequence, leading to targeted therapies based on genetic markers. Progress in immunology, particularly in using molecular proteins for treating autoimmune diseases and cancer, has further fueled the infusion market's rapid evolution.

Coleman:

From a technology standpoint, key innovations are driving our modernization efforts. One major shift in pharmaceutical manufacturing is automation, particularly AI-driven models. AI boosts efficiency and cost-effectiveness while prioritizing patient care. It also enhances accuracy in drug formulation, ensuring consistency across multiple pharmacy locations.

Beyond formulation, AI-driven predictive analytics improve financial forecasting, inventory management and specialty care programs by accurately predicting demand and optimizing supply chain management.

What Are Some Recent Challenges You Have Faced In Managing And Utilizing Data Across ER's Operations And How Has Your Team Worked To Overcome Them? Cooper:

Managing a complex business like home infusion across an entire pharmacy enterprise presents significant challenges. Previously, we received 25 to 30 reports daily, making it difficult to consolidate data for informed decision-making. Without an integrated system, business insights were limited. Partnering with Coleman and his team, we have implemented a seamless data solution that centralizes reporting. Having all data in a single platform is transformative. It allows us to focus on running the business rather than compiling reports.

Coleman:

My challenge was transforming fragmented reporting into a unified, automated system while gaining leadership buy-in. When I joined Amerita last March, there was no enterprise data services team. My mission was to centralize reporting and business intelligence, as previous reports were Excelbased and manually generated, causing inconsistencies. To address this, we built a dedicated team and launched a custom Power BI application, consolidating reports into one system. This effort streamlined processes, improved accuracy and provided real-time insights. Our goal is to create a ‘single pane of glass’ for viewing all key metrics in one place, enhancing visibility across the entire operation.

What Advice Would You Offer To Your Peers In The Industry For Achieving Success Or Strategies They Should Implement?

Cooper:

The top priority should be investing in technology, which can be costly but drives growth in unexpected ways. The second priority is understanding the business by identifying missing metrics. Delving into operations can uncover critical data that improves decision-making and efficiency. Collaboration with IT is key.

Coleman:

If I were to advise other companies, especially startups, I would emphasize that investing in technology is crucial— but it can’t happen in a vacuum. The same goes for developing an operational structure. A strong, trusted partnership among leadership ensures that six months down the line, you don’t look back and say, “We wish we had known that sooner.”